戻る Agenda
Session 5: CMC Requirements for an IND
Session Chair(s)
Albert S. Yehaskel, MBA
President and CEO
Refuah Global Pharmaceutical Development, Inc., United States
Part A: Drug Substance
- Part A of the IND will discuss in detail how to design the Drug Substance portion of an IND with real examples
- Part B of the IND will discuss in detail how to design the Drug Product portion of an IND with real examples
- Part C of the IND will discuss in detail how to design the Placebo portion of an IND in the event placebos are used in clinical trials